b'<?xml version="1.0" encoding="utf-8"?>\n<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">\n<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">\n    \n    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />\n        <!-- AppResources meta begin -->\n        <script type="text/javascript">var ncbi_startTime = new Date();</script>\n        <!-- AppResources meta end -->\n        \n        <!-- TemplateResources meta begin -->\n        <meta name="paf_template" content="" />\n\n        <!-- TemplateResources meta end -->\n        \n        <!-- Logger begin -->\n        <meta name="ncbi_db" content="pmc" /><meta name="ncbi_pdid" content="article" /><meta name="ncbi_acc" content="" /><meta name="ncbi_domain" content="ccforum" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/articles/PMC2481447/" /><meta name="ncbi_app" content="pmc" />\n        <!-- Logger end -->\n        \n        <title>A phase 1 trial of nebulised heparin in acute lung injury</title>\n        \n        <!-- AppResources external_resources begin -->\n        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>\n\n        <!-- AppResources external_resources end -->\n        \n        <!-- Page meta begin -->\n        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2481447/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Critical Care" /><meta name="citation_title" content="A phase 1 trial of nebulised heparin in acute lung injury" /><meta name="citation_authors" content="Barry Dixon, John D Santamaria, Duncan J Campbell" /><meta name="citation_date" content="2008" /><meta name="citation_issue" content="3" /><meta name="citation_volume" content="12" /><meta name="citation_firstpage" content="R64" /><meta name="citation_doi" content="10.1186/cc6894" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC2481447/?report=abstract" /><meta name="citation_pmid" content="18460218" /><meta name="DC.Title" content="A phase 1 trial of nebulised heparin in acute lung injury" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="BioMed Central" /><meta name="DC.Contributor" content="Barry Dixon" /><meta name="DC.Contributor" content="John D Santamaria" /><meta name="DC.Contributor" content="Duncan J Campbell" /><meta name="DC.Date" content="2008" /><meta name="DC.Identifier" content="10.1186/cc6894" /><meta name="DC.Language" content="en" /><meta property="og:title" content="A phase 1 trial of nebulised heparin in acute lung injury" /><meta property="og:type" content="article" /><meta property="og:description" content="Animal studies of acute lung injury (ALI) suggest nebulised heparin may limit damage from fibrin deposition in the alveolar space and microcirculation. No human studies have been undertaken to date. We assessed the feasibility, safety and potential anticoagulant ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2481447/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbi" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print" /><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:\'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/\'" /><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css" /><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-ccforum.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">\n        div.pmc_para_cit li.highlight,\n        div.pmc_para_cit li.highlight .one_line_source\n        { background: #E0E0E0; }\n        a.bibr.highlight { background: #E0E0E0; } \n      </style><meta name="cited_in_systematic_reviews" content="" /><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC2481447/epub/" /><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC2481447/pdf/cc6894.pdf" />\n\n        <!-- Page meta end -->\n    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="8A1B1B43E99AB9710000000005250522.m_8" />\n<meta name=\'referrer\' content=\'origin-when-cross-origin\'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print" /></head>\n    <body class="article">\n        <div class="grid">\n            <div class="col twelve_col nomargin shadow">\n                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->\n                <div class="sysmessages">\n                    <noscript>\n\t<p class="nojs">\n\t<strong>Warning:</strong>\n\tThe NCBI web site requires JavaScript to function. \n\t<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>\n\t</p>\n\t</noscript>\n                </div>\n                <!--/.sysmessage-->\n                <div class="wrap">\n                    <div class="page">\n                        <div class="top">\n                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main\n                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to\n                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>\n                            <div class="header">\n    <div class="res_logo">\n  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>\n  <div class="NLMLogo">\n    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>\n    <br />\n    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>\n  </div>\n</div>\n    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" class="last" data-ac_dict="pmc-search-autocomplete">PMC</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:\'pmc-search-autocomplete\',disableUrl:\'NcbiSearchBarAutoComplCtrl\'" autocomplete="off" data-sbconfig="ds:\'no\',pjs:\'no\',afs:\'yes\'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>\n                        <a href="/pmc/advanced/">Advanced</a>\n                    </li><li>\n                        <a href="/pmc/journals/">Journal list</a>\n                    </li><li class="help">\n                        <a target="_blank" href="/books/NBK3825/">Help</a>\n                    </li></ul></div>\n</div>\n\n                            \n                            \n                        <!--<component id="Page" label="headcontent"/>-->\n                            \n                        </div>\n                        <div class="content">\n                            <!-- site messages -->\n                            <div class="container">\n    <div id="maincontent" class="content eight_col col">\n        <div class="navlink-box">\n            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="archive"><a class="navlink" href="/pmc/journals/9/">Crit Care</a></li><li class="issue-page"><a class="navlink" href="/pmc/issues/169506/">v.12(3); 2008</a></li><li class="accid">PMC2481447</li></ul>\n        </div>\n\n        <!-- Journal banner -->\n        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-ccforum.png" alt="Logo of ccforum" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher\'s site" title="Link to Publisher\'s site" shape="default" coords="0,0,499,74" href="https://ccforum.biomedcentral.com/" target="pmc_ext" ref="reftype=publisher&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> </div>\n        \n        <!--component id=\'MainPortlet\' label=\'search-reference\'/-->\n        \n        <!-- Book content -->\n        <div class="">\n            \n        \n            \n            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [\'h2\'], headingExclude: \':hidden\'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><div><span class="cit"><span id="pmcmata">Crit Care</span>. 2008; 12(3): R64. </span></div><div><span class="fm-vol-iss-date">Published online 2008 May 6. </span>  <span class="doi">doi:\xc2\xa0<a href="//dx.doi.org/10.1186%2Fcc6894" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1186/cc6894</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC2481447</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/18460218">18460218</a></div></div></div></div><h1 class="content-title">A phase 1 trial of nebulised heparin in acute lung injury</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Dixon%20B%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18460218" id="A1" class="affpopup" co-rid="_co_idm139684692497664" co-class="co-affbox">Barry Dixon</a>,<sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup><sup>1</sup> <a href="/pubmed/?term=Santamaria%20JD%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18460218" id="A2" class="affpopup" co-rid="_co_idm139684734147312" co-class="co-affbox">John D Santamaria</a>,<sup>1</sup> and  <a href="/pubmed/?term=Campbell%20DJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18460218" id="A3" class="affpopup" co-rid="_co_idm139684688405872" co-class="co-affbox">Duncan J Campbell</a><sup>2</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm139684692497664"><h3 class="no_margin">Barry Dixon</h3><p><sup>1</sup>Department of Intensive Care, St Vincent\'s Hospital, 41 Victoria Parade, Melbourne 3065, Australia</p><div>Find articles by <a href="/pubmed/?term=Dixon%20B%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18460218">Barry Dixon</a></div></div><div id="_co_idm139684734147312"><h3 class="no_margin">John D Santamaria</h3><p><sup>1</sup>Department of Intensive Care, St Vincent\'s Hospital, 41 Victoria Parade, Melbourne 3065, Australia</p><div>Find articles by <a href="/pubmed/?term=Santamaria%20JD%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18460218">John D Santamaria</a></div></div><div id="_co_idm139684688405872"><h3 class="no_margin">Duncan J Campbell</h3><p><sup>2</sup>StVincent\'s Institute of Medical Research, 41 Victoria Parade, Melbourne 3065, Australia</p><div>Find articles by <a href="/pubmed/?term=Campbell%20DJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18460218">Duncan J Campbell</a></div></div></div></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm139684715139760_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm139684715139760_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm139684715139760_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm139684715139760_ai" style="display:none"><div class="fm-affl" lang="en" id="I1"><sup>1</sup>Department of Intensive Care, St Vincent\'s Hospital, 41 Victoria Parade, Melbourne 3065, Australia</div><div class="fm-affl" lang="en" id="I2"><sup>2</sup>StVincent\'s Institute of Medical Research, 41 Victoria Parade, Melbourne 3065, Australia</div><div><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup>Corresponding author.</div><div><span class="contrib-email" id="A1">Barry Dixon: <a href="mailto:dev@null" data-email="ua.gro.mhvs@noxid.yrrab" class="oemail">ua.gro.mhvs@noxid.yrrab</a>; </span> <span class="contrib-email" id="A2">John D Santamaria: <a href="mailto:dev@null" data-email="ua.gro.mhvs@airamatnas.nhoj" class="oemail">ua.gro.mhvs@airamatnas.nhoj</a>; </span> <span class="contrib-email" id="A3">Duncan J Campbell: <a href="mailto:dev@null" data-email="ua.ude.ivs@llebpmacd" class="oemail">ua.ude.ivs@llebpmacd</a></span> </div></div><div class="fm-article-notes fm-panel hide half_rhythm" id="idm139684715139760_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2008 Feb 12; Revisions requested 2008 Mar 20; Revised 2008 Apr 2; Accepted 2008 May 6.</div></div><div class="permissions fm-panel half_rhythm hide" id="idm139684715139760_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a>  &#x000a9; 2008 Dixon et al.; licensee BioMed Central Ltd.</div><div class="license half_rhythm"><p id="__p1">This is an open access article distributed under the terms of the Creative Commons Attribution License (<a href="http://creativecommons.org/licenses/by/2.0" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI" target="_blank">http://creativecommons.org/licenses/by/2.0</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>This article has been <a href="/pmc/articles/PMC2481447/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="idm139684689732336" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139684689732336title">Abstract</h2><!--article-meta--><div><div id="__sec1" class="sec sec-first"><h3 id="__sec1title">Introduction</h3><p id="__p2" class="p p-first-last">Animal studies of acute lung injury (ALI) suggest nebulised heparin may limit damage from fibrin deposition in the alveolar space and microcirculation. No human studies have been undertaken to date. We assessed the feasibility, safety and potential anticoagulant effects of administration of nebulised heparin to patients with ALI.</p></div><div id="__sec2" class="sec"><h3 id="__sec2title">Methods</h3><p id="__p3" class="p p-first-last">An open label phase 1 trial of four escalating doses of nebulised heparin was performed. A total of 16 ventilated patients with ALI were studied. The first group was administered a total of 50,000 U/day, the second group 100,000 U/day, the third group 200,000 U/day and the fourth group 400,000 U/day. Assessments of lung function included the PaO<sub>2</sub>/FiO<sub>2 </sub>ratio, lung compliance and the alveolar dead space fraction. Monitoring of anticoagulation included the activated partial thromboplastin time (APTT) and the thrombin clotting time. Bronchoalveolar lavage fluid was collected and the prothrombin fragment and tissue plasminogen activator levels were assessed. Analysis of variance was used to compare the effects of dose.</p></div><div id="__sec3" class="sec"><h3 id="__sec3title">Results</h3><p id="__p4" class="p p-first-last">No serious adverse events occurred for any dose. The changes over time for the PaO<sub>2</sub>/FiO<sub>2 </sub>ratio, lung compliance and the alveolar dead space fraction levels were similar for all doses. A trend to increased APTT and thrombin clotting time levels was present with higher doses (<em>P </em>= 0.09 and <em>P </em>= 0.1, respectively). For the highest dose, the APTT reached 64 seconds; following cessation of nebulised heparin, the APTT fell to 39 seconds (<em>P </em>= 0.06). In bronchoalveolar lavage samples a trend to reduced prothrombin fragment levels was present with higher doses (<em>P </em>= 0.1), while tissue plasminogen activator levels were similar for all doses.</p></div><div id="__sec4" class="sec"><h3 id="__sec4title">Conclusion</h3><p id="__p5" class="p p-first-last">Administration of nebulised heparin to mechanically ventilated patients with ALI is feasible. Nebulised heparin was not associated with any serious adverse events, and at higher doses it increased APTT levels. Larger trials are required to further investigate the safety and efficacy of nebulised heparin. In these trials due consideration must be given to systemic anticoagulant effects.</p></div><div id="__sec5" class="sec sec-last"><h3 id="__sec5title">Trial registration</h3><p id="__p6" class="p p-first-last">Australian Clinical trials registry ACTRN12606000388516.</p></div></div></div><div id="__sec6" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec6title">Introduction</h2><p id="__p7" class="p p-first">Acute lung injury (ALI) is a serious clinical problem. Estimates are that 190,600 cases of ALI develop in the United States each year, which are associated with 74,500 deaths and 3.6 million hospital days [<a href="#B1" rid="B1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472825">1</a>]. The 28-day mortality for ALI is 32% [<a href="#B2" rid="B2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472837">2</a>]. There is currently no method to prevent or treat ALI</p><p id="__p8">ALI is characterised by the rapid onset of respiratory distress in the setting of an inflammatory insult to the lungs [<a href="#B3" rid="B3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472833">3</a>,<a href="#B4" rid="B4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472826">4</a>]. Inflammatory insults include sepsis, trauma, hypotension, cardiopulmonary bypass, pancreatitis, aspiration and multiple transfusions. Septic insults are by the commonest cause of ALI. Pneumonia triggers 30% of cases, and sepsis elsewhere in the body causes 32% of cases [<a href="#B2" rid="B2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472827">2</a>]</p><p id="__p9">One mechanism by which inflammation causes ALI is deposition of fibrin in the alveolar space and microcirculation. Fibrin deposition in the alveolar sacs gives rise to a hyaline membrane, and deposition in the microvasculature results in thrombosis [<a href="#B5" rid="B5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472832">5</a>-<a href="#B14" rid="B14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472834">14</a>]. Nebulised heparin may limit fibrin deposition in the alveolar space and microcirculation through heparin\'s anticoagulant and fibrinolytic actions [<a href="#B15" rid="B15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472829">15</a>-<a href="#B18" rid="B18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472836">18</a>]. Studies in animal models of ALI have demonstrated that nebulised heparin improved the PaO<sub>2</sub>/FiO<sub>2 </sub>ratio and reduced histological damage [<a href="#B19" rid="B19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472835">19</a>,<a href="#B20" rid="B20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472812">20</a>]. In addition, in the setting of lung injury triggered by cardiac surgery, a preoperative heparin infusion reduced evidence of pulmonary microvascular thrombosis [<a href="#B21" rid="B21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472828">21</a>].</p><p id="__p10" class="p p-last">We are unaware of previous trials of nebulised heparin in patients with ALI. We therefore undertook the present trial to assess the feasibility, safety and potential anticoagulant effects of nebulised heparin in mechanically ventilated patients with ALI. In addition, we assessed the effects on intrapulmonary coagulation activation and fibrinolysis.</p></div><div id="__sec7" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec7title">Materials and methods</h2><p id="__p11" class="p p-first">The study was approved by the St Vincent\'s Hospital Human Research Ethics Committee. Consent was obtained from the patient or next of kin before participation in the study.</p><p id="__p12" class="p">The present study was an open-label, escalating-dosage phase 1 trial of nebulised heparin (heparin sodium, 25,000 U/ml; CP Pharmaceuticals Ltd, Wrexham, UK) in mechanically ventilated patients with ALI. Four doses were studied. Each dose was assessed in four patients over 2 days. The first group was administered 50,000 U/day, as 25,000 U 12 hourly (four nebulisations); the second group received 100,000 U/day, as 50,000 U 12 hourly (four nebulisations); the third group received 200,000 U/day, as 100,000 U 12 hourly (four nebulisations); and the fourth group was administered 400,000 U/day, as 100,000 U 6 hourly (eight nebulisations). The final nebulisation of heparin was administered at 36 hours from baseline in the 50,000 U/day, 100,000 U/day and 200,000 U/day groups, and at 42 hours in the 400,000 U/day group.</p><div id="__sec8" class="sec"><h3 id="__sec8title">Subjects</h3><p id="__p13" class="p p-first">We studied patients admitted to the intensive care unit that met the following inclusion and exclusion criteria.</p><p id="__p14">The inclusion criterion was the initiation of mechanical ventilation for acute respiratory dysfunction characterised by a PaO<sub>2</sub>/FiO<sub>2 </sub>ratio &#x0003c; 300 mmHg, where the acute respiratory dysfunction was primarily due to a direct or indirect inflammatory insult to the lung.</p><p id="__p15" class="p p-last">The exclusion criteria were &#x0003e; 48 hours since the inclusion criterion was met; hypoxemia predominantly due to a cause other than ALI, such as congestive heart failure, pulmonary embolism, chronic obstructive airways disease or asthma; systemic anticoagulation (including activated protein C), potential need for haemofiltration and therefore anticoagulation; pulmonary haemorrhage in the previous 3 months, uncontrolled bleeding, significant bleeding disorder; allergy to heparin, including heparin-induced thrombocytopenia; age &#x0003c; 18 years or &#x0003e; 85 years; patient unlikely to survive 96 hours; bronchoscopy not possible due to severe hypoxia; previous intubation and ventilation during current admission; noninvasive ventilation for more than 36 hours prior to intubation; or pregnancy.</p></div><div id="__sec9" class="sec"><h3 id="__sec9title">Nebulisation</h3><p id="__p16" class="p p-first-last">Heparin was nebulised with an Aeroneb Pro Nebulizer (Aerogen Ltd, Galway, Ireland) over 30 minutes. The nebuliser was placed in the inspiratory line 12 cm from the Y of the circuit. The heat and moisture exchanger was removed during nebulisation. Patients were ventilated in a pressure-support mode of ventilation and upper pressure levels were maintained at or below 35 cmH<sub>2</sub>O.</p></div><div id="__sec10" class="sec"><h3 id="__sec10title">Lung function</h3><p id="__p17" class="p p-first-last">The P<sub>a</sub>O<sub>2</sub>/F<sub>i</sub>O<sub>2 </sub>ratio, lung compliance and the alveolar dead space fraction were measured at baseline and at 2, 6, 10, 14, 18, 22, 26, 30, 34, 28, 42 and 46 hours. We measured the alveolar dead space fraction because previous studies have suggested this variable may reflect the extent of microvascular thrombosis in ALI [<a href="#B21" rid="B21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472831">21</a>,<a href="#B22" rid="B22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472817">22</a>]. Evidence of blood staining of respiratory secretions was assessed by the bedside nurse following routine pulmonary suctioning.</p></div><div id="__sec11" class="sec"><h3 id="__sec11title">Anticoagulant effects</h3><p id="__p18" class="p p-first-last">The activated partial thromboplastin time (APTT) and the thrombin clotting time (TCT) were assessed at the same time points as those of lung function, and at 50, 54 and 58 hours in the 400,000 U/day group.</p></div><div id="__sec12" class="sec"><h3 id="__sec12title">Lung haemostatic responses</h3><p id="__p19" class="p p-first-last">Prothrombin fragments (PTF) and tissue plasminogen activator (t-PA) levels in bronchoalveolar lavage (BAL) fluid were assessed at baseline and following the final nebulisation (BAL was undertaken on average 7.6 &#x000b1; 5 hours following the final nebulisation).</p></div><div id="__sec13" class="sec"><h3 id="__sec13title">Lung compliance and alveolar dead space fraction</h3><p id="__p20" class="p p-first-last">Standard formulae were used to calculate lung compliance. The alveolar dead space fraction was measured with the Cosmo Plus Respironics monitor (Novametrix Medical Systems, Wallingford, CT, USA) [<a href="#B21" rid="B21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472821">21</a>].</p></div><div id="__sec14" class="sec"><h3 id="__sec14title">Bronchoalveolar lavage</h3><p id="__p21" class="p p-first-last">The bronchoscope was wedged in the distal airway. The initial 25 ml of warm saline injected was discarded. Five further 25 ml aliquots were instilled and aspirated. A portion of the aspirated fluid was spun at 1,500 &#x000d7; <em>g </em>for 10 minutes at 4&#x000b0;C. The supernatant was stored at -80&#x000b0;C. Samples were assayed by ELISAs for PTF levels (Enzygnost F1 + 2 monoclonal assays; Behring, Marburg, Germany) and for t-PA antigen levels (TintElize tPA, Biopool International, Ventura, CA, USA).</p></div><div id="__sec15" class="sec sec-last"><h3 id="__sec15title">Statistical analysis</h3><p id="__p22" class="p p-first">Based on previous studies we determined that four patients in each group would be adequate to detect a major anticoagulant effect [<a href="#B23" rid="B23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472818">23</a>,<a href="#B24" rid="B24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_314770689">24</a>]. Analysis of variance was used to compare the effect of heparin dose on the P<sub>a</sub>O<sub>2</sub>/F<sub>i</sub>O<sub>2 </sub>ratio, lung compliance, the alveolar dead space fraction, the APTT, the TCT and intrapulmonary PTF and t-PA levels. Fisher\'s exact test compared categorical variables. Student\'s <em>t </em>test compared normally distributed variables.</p><p id="__p23" class="p p-last">Data are reported as the mean &#x000b1; standard deviation. Statistical analysis was performed with the JMP program (SAS Institute, Inc., Cary, NC, USA).</p></div></div><div id="__sec16" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec16title">Results</h2><div id="__sec17" class="sec sec-first"><h3 id="__sec17title">Patient characteristics</h3><p id="__p24" class="p p-first">Sixteen patients were enrolled. The mean patient age was 58 &#x000b1; 14 years, and the Acute Physiology and Chronic Health Evaluation Score II was 21 &#x000b1; 7. The baseline P<sub>a</sub>O<sub>2</sub>/F<sub>i</sub>O<sub>2 </sub>ratio was 183 &#x000b1; 66 mmHg, lung compliance was 26 &#x000b1; 14 ml/cmH<sub>2</sub>O and the alveolar dead space fraction was 0.23 &#x000b1; 0.1. Prophylactic subcutaneous heparin was administered to 14 of the 16 patients studied. The commonest aetiological factor for ALI was pneumonia (Table <a href="/pmc/articles/PMC2481447/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">(Table1).</span></span><span>1</span></a>). The time from intubation to initial heparin nebulisation was 22 &#x000b1; 15 hours. The mean mechanical ventilation time was 10 &#x000b1; 9 days, the intensive care length of stay was 12 &#x000b1; 8 days and the hospital length of stay was 28 &#x000b1; 14 days. The tracheostomy rate was 63% and the hospital mortality was 43%.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T1"><h3>Table 1</h3><!--caption a7--><div class="caption"><p id="__p25">Baseline and microbiological characteristics of patients</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139684727726560" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><td align="left" rowspan="1" colspan="1">Variable</td><td align="left" colspan="4" rowspan="1">Dose</td><td align="left" rowspan="1" colspan="1">Combined <em>n </em>(%)</td></tr><tr><td rowspan="1" colspan="1"></td><td colspan="5" rowspan="1"><hr /></td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">50,000 U/day</td><td align="left" rowspan="1" colspan="1">100,000 U/day</td><td align="left" rowspan="1" colspan="1">200,000 U/day</td><td align="left" rowspan="1" colspan="1">400,000 U/day</td><td rowspan="1" colspan="1"></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Number of patients</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1">57.7 &#x000b1; 17.3</td><td align="left" rowspan="1" colspan="1">61.3 &#x000b1; 14.2</td><td align="left" rowspan="1" colspan="1">54.3 &#x000b1; 17.6</td><td align="left" rowspan="1" colspan="1">60.0 &#x000b1; 13.0</td><td align="left" rowspan="1" colspan="1">58.3 &#x000b1; 14.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">8 (50)</td></tr><tr><td align="left" rowspan="1" colspan="1">Acute Physiological and Chronic Health Evaluation II score</td><td align="left" rowspan="1" colspan="1">22.3 &#x000b1; 6.0</td><td align="left" rowspan="1" colspan="1">21.8 &#x000b1; 8.7</td><td align="left" rowspan="1" colspan="1">18.3 &#x000b1; 10</td><td align="left" rowspan="1" colspan="1">20.0 &#x000b1; 3.4</td><td align="left" rowspan="1" colspan="1">20.6 &#x000b1; 7.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Subcutaneous heparin</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">14 (88)</td></tr><tr><td align="left" rowspan="1" colspan="1">Arterial to inspired oxygen ratio (mmHg)</td><td align="left" rowspan="1" colspan="1">159 &#x000b1; 37</td><td align="left" rowspan="1" colspan="1">143 &#x000b1; 48</td><td align="left" rowspan="1" colspan="1">207 &#x000b1; 79</td><td align="left" rowspan="1" colspan="1">226 &#x000b1; 75</td><td align="left" rowspan="1" colspan="1">183 &#x000b1; 66</td></tr><tr><td align="left" rowspan="1" colspan="1">Lung compliance (ml/cmH<sub>2</sub>O)</td><td align="left" rowspan="1" colspan="1">30 &#x000b1; 7</td><td align="left" rowspan="1" colspan="1">19 &#x000b1; 5</td><td align="left" rowspan="1" colspan="1">37 &#x000b1; 21</td><td align="left" rowspan="1" colspan="1">22 &#x000b1; 14</td><td align="left" rowspan="1" colspan="1">26 &#x000b1; 14</td></tr><tr><td align="left" rowspan="1" colspan="1">Alveolar dead space fraction</td><td align="left" rowspan="1" colspan="1">0.15 &#x000b1; 0.04</td><td align="left" rowspan="1" colspan="1">0.3 &#x000b1; 0.10</td><td align="left" rowspan="1" colspan="1">0.17 &#x000b1; 0.07</td><td align="left" rowspan="1" colspan="1">0.24 &#x000b1; 0.1</td><td align="left" rowspan="1" colspan="1">0.23 &#x000b1; 0.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (&#x003bc;mol/l)</td><td align="left" rowspan="1" colspan="1">80 &#x000b1; 45</td><td align="left" rowspan="1" colspan="1">56 &#x000b1; 14</td><td align="left" rowspan="1" colspan="1">130 &#x000b1; 154</td><td align="left" rowspan="1" colspan="1">97 &#x000b1; 45</td><td align="left" rowspan="1" colspan="1">91 &#x000b1; 80</td></tr><tr><td align="left" rowspan="1" colspan="1">Activated partial thromboplastin time (s)</td><td align="left" rowspan="1" colspan="1">38 &#x000b1; 7</td><td align="left" rowspan="1" colspan="1">37 &#x000b1; 6</td><td align="left" rowspan="1" colspan="1">44 &#x000b1; 7</td><td align="left" rowspan="1" colspan="1">47 &#x000b1; 20</td><td align="left" rowspan="1" colspan="1">41 &#x000b1; 11</td></tr><tr><td align="left" rowspan="1" colspan="1">Thrombin clotting time (s)</td><td align="left" rowspan="1" colspan="1">17 &#x000b1; 2</td><td align="left" rowspan="1" colspan="1">21 &#x000b1; 3</td><td align="left" rowspan="1" colspan="1">20 &#x000b1; 10</td><td align="left" rowspan="1" colspan="1">19 &#x000b1; 3</td><td align="left" rowspan="1" colspan="1">19 &#x000b1; 5</td></tr><tr><td align="left" rowspan="1" colspan="1">Acute lung injury cause</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Pneumonia</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">10 (63)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Sepsis</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2 (13)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Pancreatitis</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2 (13)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Empyema</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2 (13)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Aspiration</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Surgical admission</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">6 (38)</td></tr><tr><td align="left" rowspan="1" colspan="1">Microbiology</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Gram-negative</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">4 (25)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Gram-positive</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">4 (25)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Other</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">3 (19)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No pathogen detected</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">5 (31)</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood culture-positive</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2 (12)</td></tr></tbody></table></div><div id="largeobj_idm139684727726560" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2481447/table/T1/?report=objectonly">Open in a separate window</a></div></div></div><div id="__sec18" class="sec"><h3 id="__sec18title">Lung function</h3><p id="__p26" class="p p-first">The changes over time in the P<sub>a</sub>O<sub>2</sub>/F<sub>i</sub>O<sub>2 </sub>ratio, lung compliance and the alveolar dead space fraction were similar for all doses studied. There were no statistically significant differences found for the dosage or for the interaction between dosage and time (Figures <a href="/pmc/articles/PMC2481447/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -4em;">(Figures1</span></span><span>1</span></a> to <a href="/pmc/articles/PMC2481447/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -1em;">to3</span></span><span>3</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F1" co-legend-rid="lgnd_F1"><a href="/pmc/articles/PMC2481447/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139684684213456" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2481447_cc6894-1.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is cc6894-1.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2481447/bin/cc6894-1.jpg" /></a></div><div id="largeobj_idm139684684213456" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2481447/figure/F1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="/pmc/articles/PMC2481447/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Figure 1</a></div><!--caption a7--><div class="caption"><p id="__p27">Changes in arterial to inspired oxygen ratio with nebulised heparin dosage. Percentage change from baseline in the arterial to inspired oxygen ratio (P<sub>a</sub>O<sub>2</sub>/F<sub>i</sub>O<sub>2</sub>) (mean &#x000b1; standard deviation).</p></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F3" co-legend-rid="lgnd_F3"><a href="/pmc/articles/PMC2481447/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139684689328864" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2481447_cc6894-3.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is cc6894-3.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2481447/bin/cc6894-3.jpg" /></a></div><div id="largeobj_idm139684689328864" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2481447/figure/F3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F3"><div><a class="figpopup" href="/pmc/articles/PMC2481447/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3">Figure 3</a></div><!--caption a7--><div class="caption"><p id="__p29">Changes in alveolar dead space fraction with nebulised heparin dosage. Percentage change from baseline in the alveolar dead space fraction (ADSF) (mean &#x000b1; standard deviation).</p></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F2" co-legend-rid="lgnd_F2"><a href="/pmc/articles/PMC2481447/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139684682520960" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2481447_cc6894-2.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is cc6894-2.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2481447/bin/cc6894-2.jpg" /></a></div><div id="largeobj_idm139684682520960" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2481447/figure/F2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="/pmc/articles/PMC2481447/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Figure 2</a></div><!--caption a7--><div class="caption"><p id="__p28">Changes in lung compliance with nebulised heparin dosage. Percentage change from baseline in the lung compliance over time for each dose (mean &#x000b1; standard deviation).</p></div></div></div><p id="__p30" class="p p-last">One patient in the 400,000 U/day group developed blood-stained respiratory secretions after the seventh dose. This was not associated with any deterioration in lung function. The blood staining resolved following withdrawal of nebulised heparin.</p></div><div id="__sec19" class="sec"><h3 id="__sec19title">Anticoagulant effects</h3><p id="__p31" class="p p-first">The mean APTT for each group following the final nebulisation, in order of increasing dose, was 34 seconds (normal range &#x0003c; 35 seconds), 41 seconds, 48 seconds and 64 seconds (<em>P </em>= 0.09, analysis of variance, comparison by dose) (Figure <a href="/pmc/articles/PMC2481447/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure4).</span></span><span>4</span></a>). The mean TCT for each group following the final nebulisation, in order of increasing dose, was 18 seconds (normal range &#x0003c; 21 seconds), 23 seconds, 50 seconds and 48 seconds (<em>P </em>= 0.1, analysis of variance, comparison by dose) (Figure <a href="/pmc/articles/PMC2481447/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure5).</span></span><span>5</span></a>). For the higher dose groups, both the APTT and TCT fell following cessation of nebulised heparin. For the highest dose, the APTT fell from 64 seconds to 39 seconds (<em>P </em>= 0.06) (Figure <a href="/pmc/articles/PMC2481447/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure4</span></span><span>4</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F4" co-legend-rid="lgnd_F4"><a href="/pmc/articles/PMC2481447/figure/F4/" target="figure" rid-figpopup="F4" rid-ob="ob-F4"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139684692848896" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2481447_cc6894-4.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is cc6894-4.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2481447/bin/cc6894-4.jpg" /></a></div><div id="largeobj_idm139684692848896" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2481447/figure/F4/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F4"><div><a class="figpopup" href="/pmc/articles/PMC2481447/figure/F4/" target="figure" rid-figpopup="F4" rid-ob="ob-F4">Figure 4</a></div><!--caption a7--><div class="caption"><p id="__p32">Changes in activated partial thromboplastin time with nebulised heparin dosage. Upper: Change in the activated partial thromboplastin time (APTT) over time. The last dose of heparin was given at 36 hours for all groups except the 400,000 U/day group, in which it was administered at 42 hours (mean levels; <em>P </em>= 0.06, comparison of 46-hour and 58-hour timepoints in the 400,000 U/day group). Lower: APTT at baseline and following the final dose of nebulised heparin (<em>P </em>= 0.09, analysis of variance comparison by dose, mean and standard deviation).</p></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F5" co-legend-rid="lgnd_F5"><a href="/pmc/articles/PMC2481447/figure/F5/" target="figure" rid-figpopup="F5" rid-ob="ob-F5"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139684728994032" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2481447_cc6894-5.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is cc6894-5.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2481447/bin/cc6894-5.jpg" /></a></div><div id="largeobj_idm139684728994032" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2481447/figure/F5/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F5"><div><a class="figpopup" href="/pmc/articles/PMC2481447/figure/F5/" target="figure" rid-figpopup="F5" rid-ob="ob-F5">Figure 5</a></div><!--caption a7--><div class="caption"><p id="__p33">Changes in thrombin clotting time with nebulised heparin dosage. Upper: Change in the thrombin clotting time (TCT) over time. The last dose of heparin was given at 36 hours for all groups except the 400,000 U/day group, in which it was administered at 42 hours (mean levels). Lower: TCT at baseline and following the final dose of nebulised heparin (<em>P </em>= 0.1, analysis of variance comparison by dose, mean and standard deviation).</p></div></div></div></div><div id="__sec20" class="sec sec-last"><h3 id="__sec20title">Bronchoalveolar lavage</h3><p id="__p34" class="p p-first">The PTF levels in BAL fluid in the 50,000 U/day group were higher following the final nebulisation, while in the 100,000 U/day, 200,000 U/day and 400,000 U/day groups the PTF levels remained similar to baseline levels following the final nebulisation (<em>P </em>= 0.1, analysis of variance, comparison by dose) (Figure <a href="/pmc/articles/PMC2481447/figure/F6/" target="figure" class="fig-table-link figpopup" rid-figpopup="F6" rid-ob="ob-F6" co-legend-rid="lgnd_F6"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure6).</span></span><span>6</span></a>). The t-PA levels were similar to baseline levels for all doses following the final nebulisation (Figure <a href="/pmc/articles/PMC2481447/figure/F7/" target="figure" class="fig-table-link figpopup" rid-figpopup="F7" rid-ob="ob-F7" co-legend-rid="lgnd_F7"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure7</span></span><span>7</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F6" co-legend-rid="lgnd_F6"><a href="/pmc/articles/PMC2481447/figure/F6/" target="figure" rid-figpopup="F6" rid-ob="ob-F6"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139684694088304" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is cc6894-6.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is cc6894-6.jpg" src="/pmc/articles/PMC2481447/bin/cc6894-6.jpg" /></div><div id="largeobj_idm139684694088304" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2481447/figure/F6/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F6"><div><a class="figpopup" href="/pmc/articles/PMC2481447/figure/F6/" target="figure" rid-figpopup="F6" rid-ob="ob-F6">Figure 6</a></div><!--caption a7--><div class="caption"><p id="__p35">Comparison of prothrombin fragment levels in bronchoalveolar fluid with nebulised heparin dosage. Comparison of prothrombin fragment (PTF) levels in bronchoalveolar fluid. Levels were assessed at baseline and following the final dose of nebulised heparin (<em>P </em>= 0.1, analysis of variance comparison by dose, mean and standard deviation).</p></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F7" co-legend-rid="lgnd_F7"><a href="/pmc/articles/PMC2481447/figure/F7/" target="figure" rid-figpopup="F7" rid-ob="ob-F7"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139684682968576" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is cc6894-7.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is cc6894-7.jpg" src="/pmc/articles/PMC2481447/bin/cc6894-7.jpg" /></div><div id="largeobj_idm139684682968576" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2481447/figure/F7/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F7"><div><a class="figpopup" href="/pmc/articles/PMC2481447/figure/F7/" target="figure" rid-figpopup="F7" rid-ob="ob-F7">Figure 7</a></div><!--caption a7--><div class="caption"><p id="__p36">Comparison of tissue plasminogen activator levels in bronchoalveloar fluid with nebulised heparin dosage. Comparison of tissue plasminogen activator (t-PA) levels in bronchoalveloar fluid. Levels were assessed at baseline and following the final dose of nebulised heparin (mean and standard deviation).</p></div></div></div></div></div><div id="__sec21" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec21title">Discussion</h2><p id="__p37" class="p p-first">We assessed the feasibility, safety and potential anticoagulant effects of nebulised heparin in mechanically ventilated patients with ALI. We found administration of nebulised heparin to mechanically ventilated patients with ALI was feasible, was not associated with serious adverse events, and increased APTT levels at higher doses.</p><p id="__p38">The changes in the PaO<sub>2</sub>/FiO<sub>2 </sub>ratio, lung compliance and the alveolar dead space fraction were similar for all doses. In one patient in the 400,000 U/day group, blood staining of the respiratory secretions was present after the seventh dose. This staining resolved following withdrawal of heparin.</p><p id="__p39">We found evidence of dose-dependent effects on APTT and TCT levels. For the 50,000 U/day group, the levels remained within the normal range; however, for the 100,000 U/day, 200,000 U/day and 400,000 U/day groups, the APTT and TCT levels were raised on the second day. Peak levels were reached following the final nebulisation, and thereafter levels fell. For the 400,000 U/day group, the APTT reached the therapeutic range (64 seconds) and fell acutely to 39 seconds following cessation of nebulised heparin.</p><p id="__p40">Previous clinical studies have investigated the potential of systemic anticoagulation using nebulised heparin &#x02013; to date, without success [<a href="#B23" rid="B23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472824">23</a>,<a href="#B24" rid="B24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_314770690">24</a>]. Unlike these studies we used repeated doses of nebulised heparin. Our finding that the APTT and TCT levels increased only after repeated doses suggests that pulmonary processes, such as storage of heparin in endothelial cells and metabolism by heparinases, may initially limit heparin reaching the systemic circulation. These processes may, however, become saturated following repeated heparin doses [<a href="#B25" rid="B25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472830">25</a>]. In future trials of nebulised heparin, due consideration must be given to this systemic anticoagulant effect.</p><p id="__p41">We also examined whether nebulised heparin limited coagulation and increased fibrinolysis in the lungs. For the 50,000 U/day group, the PTF levels in BAL fluid doubled from baseline levels following the final nebulisation. For the 100,000 U/day, 200,000 U/day and 400,000 U/day groups, however, the PTF levels did not increase. Previous trials in patients with ventilated-associated pneumonia also found a doubling of coagulation levels in BAL fluid over the first few days [<a href="#B26" rid="B26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472816">26</a>,<a href="#B27" rid="B27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472820">27</a>]. While inconclusive, our findings raise the possibility that nebulised heparin, at higher doses, limited coagulation activation in the lungs. Nebulised heparin did not increase t-PA levels in BAL fluid for any of the doses studied.</p><p id="__p42">One of the strengths of the present study was the nebulisation system used. The evidence of a dose-related effect on systemic APTT and TCT levels suggested significant amounts of heparin reached the alveolar spaces. This finding is consistent with previous studies [<a href="#B28" rid="B28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472819">28</a>]. Another strength of the study was the inclusion of genuinely high-risk patients with ALI. The average P<sub>a</sub>O<sub>2</sub>/F<sub>i</sub>O<sub>2 </sub>ratio at baseline was 183 mmHg, the tracheostomy rate was 63% and the hospital mortality was 43%.</p><p id="__p43">Limitations of the present study included the absence of a control group, the small number of patients enrolled and the relatively short time (2 days) over which heparin was nebulised. The size of the study reflected the need for caution, as nebulised heparin had not previously been administered to patients with ALI. Furthermore, we determined that four patients in each group would provide adequate power to detect a major anticoagulant effect. Our study was consequently too small to draw conclusions regarding efficacy or potential infrequent deleterious effects.</p><p id="__p44" class="p p-last">Previous studies in animal models of ALI have demonstrated significant improvements in pulmonary function with inhaled heparin and other glycosaminoglycans [<a href="#B19" rid="B19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472823">19</a>,<a href="#B20" rid="B20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472822">20</a>,<a href="#B29" rid="B29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472815">29</a>]. Heparin has a range of anticoagulant actions and also promotes fibrinolysis through increased t-PA levels [<a href="#B15" rid="B15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472814">15</a>-<a href="#B18" rid="B18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_153472813">18</a>]. Compared with the intravenous route, nebulisation delivers high concentrations of heparin to the alveolar space with a reduced risk of adversely effecting systemic coagulation.</p></div><div id="__sec22" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec22title">Conclusion</h2><p id="__p45" class="p p-first-last">Administration of nebulised heparin to mechanically ventilated patients with ALI is feasible. The heparin administration was not associated with any serious adverse events, and increased APTT levels at higher doses. Larger trials are required to further investigate the safety and efficacy of nebulised heparin in ALI. In these trials, due consideration must be given to systemic anticoagulant effects.</p></div><div id="__sec23" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec23title">Key messages</h2><p id="__p46" class="p p-first">&#x02022; Administration of nebulised heparin to mechanically ventilated patients with ALI is feasible and was not associated with any serious adverse events.</p><p id="__p47">&#x02022; At higher doses, nebulised heparin increased APTT levels.</p><p id="__p48" class="p p-last">&#x02022; Larger trials are required to further investigate the safety and efficacy of nebulised heparin in ALI.</p></div><div id="__sec24" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec24title">Abbreviations</h2><p id="__p49" class="p p-first-last">ALI = acute lung injury; APTT = activated partial thromboplastin time; BAL = bronchoalveolar lavage; ELISA = enzyme-linked immunosorbent assay; PaO<sub>2</sub>/FiO<sub>2 </sub>= arterial oxygen partial pressure to inspired oxygen fraction ratio; PTF = prothrombin fragments; TCT = thrombin clotting time; t-PA = tissue plasminogen activator.</p></div><div id="__sec25" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec25title">Competing interests</h2><p id="__p50" class="p p-first-last">The authors declare that they have no competing interests.</p></div><div id="__sec26" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec26title">Authors\' contributions</h2><p id="__p51" class="p p-first-last">BD designed the study, collected the data, performed the statistical analysis and drafted the manuscript. JDS and DJC participated in its design, and coordinated and helped to draft the manuscript. All authors read and approved the final manuscript.</p></div><div id="idm139684693350880" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139684693350880title">Acknowledgements</h2><div class="sec"><div id="__sec27" class="sec sec-first"><h3 id="__sec27title"></h3><p id="__p52" class="p p-first-last">The present study was supported by the St Vincent\'s Hospital Research Endowment Fund and the Intensive Care Foundation. The funding bodies had no role in the study design, data collection, analysis and interpretation of the data or in the writing and publication of the manuscript.</p></div></div></div><div id="idm139684693349328" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139684693349328title">References</h2><div class="ref-list-sec sec" id="reference-list"><ul class="back-ref-list" style="list-style-type:decimal;"><li id="B1"><span class="citation">Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD. Incidence and outcomes of acute lung injury. <span><span class="ref-journal">N Engl J Med. </span>2005;<span class="ref-vol">353</span>:1685\xe2\x80\x931693. doi: 10.1056/NEJMoa050333.</span> [<a href="/pubmed/16236739" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1056%2FNEJMoa050333" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Incidence+and+outcomes+of+acute+lung+injury&amp;author=GD+Rubenfeld&amp;author=E+Caldwell&amp;author=E+Peabody&amp;author=J+Weaver&amp;author=DP+Martin&amp;volume=353&amp;publication_year=2005&amp;pages=1685-1693&amp;pmid=16236739&amp;doi=10.1056/NEJMoa050333&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B2"><span class="citation">Bersten AD, Edibam C, Hunt T, Moran J. Incidence and mortality of acute lung injury and the acute respiratory distress syndrome in three Australian States. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2002;<span class="ref-vol">165</span>:443\xe2\x80\x93448.</span> [<a href="/pubmed/11850334" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Respir+Crit+Care+Med&amp;title=Incidence+and+mortality+of+acute+lung+injury+and+the+acute+respiratory+distress+syndrome+in+three+Australian+States&amp;author=AD+Bersten&amp;author=C+Edibam&amp;author=T+Hunt&amp;author=J+Moran&amp;volume=165&amp;publication_year=2002&amp;pages=443-448&amp;pmid=11850334&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B3"><span class="citation">Ware LB, Matthay MA. The acute respiratory distress syndrome. <span><span class="ref-journal">N Engl J Med. </span>2000;<span class="ref-vol">342</span>:1334\xe2\x80\x931349. doi: 10.1056/NEJM200005043421806.</span> [<a href="/pubmed/10793167" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1056%2FNEJM200005043421806" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=The+acute+respiratory+distress+syndrome&amp;author=LB+Ware&amp;author=MA+Matthay&amp;volume=342&amp;publication_year=2000&amp;pages=1334-1349&amp;pmid=10793167&amp;doi=10.1056/NEJM200005043421806&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B4"><span class="citation">Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>1994;<span class="ref-vol">149</span>:818\xe2\x80\x93824.</span> [<a href="/pubmed/7509706" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Respir+Crit+Care+Med&amp;title=The+American-European+Consensus+Conference+on+ARDS.+Definitions,+mechanisms,+relevant+outcomes,+and+clinical+trial+coordination&amp;author=GR+Bernard&amp;author=A+Artigas&amp;author=KL+Brigham&amp;author=J+Carlet&amp;author=K+Falke&amp;volume=149&amp;publication_year=1994&amp;pages=818-824&amp;pmid=7509706&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B5"><span class="citation">Blaisdell FW. Pathophysiology of the respiratory distress syndrome. <span><span class="ref-journal">Arch Surg. </span>1974;<span class="ref-vol">108</span>:44\xe2\x80\x9349.</span> [<a href="/pubmed/4859600" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Arch+Surg&amp;title=Pathophysiology+of+the+respiratory+distress+syndrome&amp;author=FW+Blaisdell&amp;volume=108&amp;publication_year=1974&amp;pages=44-49&amp;pmid=4859600&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B6"><span class="citation">Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, Chu CM, Hui PK, Mak KL, Lim W, Yan KW, Chan KH, Tsang NC, Guan Y, Yuen KY, Peiris JS. Lung pathology of fatal severe acute respiratory syndrome. <span><span class="ref-journal">Lancet. </span>2003;<span class="ref-vol">361</span>:1773\xe2\x80\x931778. doi: 10.1016/S0140-6736(03)13413-7.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7112492/">PMC free article</a>]</span> [<a href="/pubmed/12781536" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS0140-6736(03)13413-7" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Lung+pathology+of+fatal+severe+acute+respiratory+syndrome&amp;author=JM+Nicholls&amp;author=LL+Poon&amp;author=KC+Lee&amp;author=WF+Ng&amp;author=ST+Lai&amp;volume=361&amp;publication_year=2003&amp;pages=1773-1778&amp;pmid=12781536&amp;doi=10.1016/S0140-6736(03)13413-7&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B7"><span class="citation">Scully RE, Galdabini JJ, McNeely BU. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 22 &#x02013; 1977. <span><span class="ref-journal">N Engl J Med. </span>1977;<span class="ref-vol">296</span>:1279\xe2\x80\x931287.</span> [<a href="/pubmed/859521" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Case+records+of+the+Massachusetts+General+Hospital.+Weekly+clinicopathological+exercises.+Case+22+&#x02013;+1977&amp;author=RE+Scully&amp;author=JJ+Galdabini&amp;author=BU+McNeely&amp;volume=296&amp;publication_year=1977&amp;pages=1279-1287&amp;pmid=859521&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B8"><span class="citation">Dairaku M, Sueishi K, Tanaka K. Disseminated intravascular coagulation in newborn infants. Prevalence in autopsies and significance as a cause of death. <span><span class="ref-journal">Pathol Res Pract. </span>1982;<span class="ref-vol">174</span>:106\xe2\x80\x93115.</span> [<a href="/pubmed/7134058" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pathol+Res+Pract&amp;title=Disseminated+intravascular+coagulation+in+newborn+infants.+Prevalence+in+autopsies+and+significance+as+a+cause+of+death&amp;author=M+Dairaku&amp;author=K+Sueishi&amp;author=K+Tanaka&amp;volume=174&amp;publication_year=1982&amp;pages=106-115&amp;pmid=7134058&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B9"><span class="citation">Tomashefski JF, Jr, Davies P, Boggis C, Greene R, Zapol WM, Reid LM. The pulmonary vascular lesions of the adult respiratory distress syndrome. <span><span class="ref-journal">Am J Pathol. </span>1983;<span class="ref-vol">112</span>:112\xe2\x80\x93126.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1916312/">PMC free article</a>]</span> [<a href="/pubmed/6859225" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Pathol&amp;title=The+pulmonary+vascular+lesions+of+the+adult+respiratory+distress+syndrome&amp;author=JF+Tomashefski&amp;author=P+Davies&amp;author=C+Boggis&amp;author=R+Greene&amp;author=WM+Zapol&amp;volume=112&amp;publication_year=1983&amp;pages=112-126&amp;pmid=6859225&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B10"><span class="citation">Bone RC, Francis PB, Pierce AK. Intravascular coagulation associated with the adult respiratory distress syndrome. <span><span class="ref-journal">Am J Med. </span>1976;<span class="ref-vol">61</span>:585\xe2\x80\x93589. doi: 10.1016/0002-9343(76)90135-2.</span> [<a href="/pubmed/984062" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2F0002-9343(76)90135-2" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Med&amp;title=Intravascular+coagulation+associated+with+the+adult+respiratory+distress+syndrome&amp;author=RC+Bone&amp;author=PB+Francis&amp;author=AK+Pierce&amp;volume=61&amp;publication_year=1976&amp;pages=585-589&amp;pmid=984062&amp;doi=10.1016/0002-9343(76)90135-2&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B11"><span class="citation">Hill JD, Ratliff JL, Parrott JC, Lamy M, Fallat RJ, Koeniger E, Yaeger EM, Whitmer G. Pulmonary pathology in acute respiratory insufficiency: lung biopsy as a diagnostic tool. <span><span class="ref-journal">J Thorac Cardiovasc Surg. </span>1976;<span class="ref-vol">71</span>:64\xe2\x80\x9371.</span> [<a href="/pubmed/765628" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Thorac+Cardiovasc+Surg&amp;title=Pulmonary+pathology+in+acute+respiratory+insufficiency:+lung+biopsy+as+a+diagnostic+tool&amp;author=JD+Hill&amp;author=JL+Ratliff&amp;author=JC+Parrott&amp;author=M+Lamy&amp;author=RJ+Fallat&amp;volume=71&amp;publication_year=1976&amp;pages=64-71&amp;pmid=765628&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B12"><span class="citation">Saldeen T. The microembolism syndrome. <span><span class="ref-journal">Forensic Sci. </span>1972;<span class="ref-vol">1</span>:179\xe2\x80\x93187. doi: 10.1016/0300-9432(72)90041-6.</span> [<a href="/pubmed/5045685" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2F0300-9432(72)90041-6" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Forensic+Sci&amp;title=The+microembolism+syndrome&amp;author=T+Saldeen&amp;volume=1&amp;publication_year=1972&amp;pages=179-187&amp;pmid=5045685&amp;doi=10.1016/0300-9432(72)90041-6&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B13"><span class="citation">Archer L.  Pathological manifestations of septic shock. In: Proctor RA, editor. <span class="ref-journal">Handbook of Endotoxin.</span> Vol. 4. Elsevier Science Publishers; Philadelphia, PA, USA; 1986.  <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=Handbook+of+Endotoxin&amp;author=L+Archer&amp;publication_year=1986&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B14"><span class="citation">Yoshikawa T, Tanaka KR, Guze LB. Infection and disseminated intravascular coagulation. <span><span class="ref-journal">Medicine. </span>1971;<span class="ref-vol">50</span>:237\xe2\x80\x93258. doi: 10.1097/00005792-197107000-00001.</span> [<a href="/pubmed/4947125" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1097%2F00005792-197107000-00001" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Medicine&amp;title=Infection+and+disseminated+intravascular+coagulation&amp;author=T+Yoshikawa&amp;author=KR+Tanaka&amp;author=LB+Guze&amp;volume=50&amp;publication_year=1971&amp;pages=237-258&amp;pmid=4947125&amp;doi=10.1097/00005792-197107000-00001&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B15"><span class="citation">Cadroy Y, Gaspin D, Dupouy D, Lormeau JC, Boneu B, Sie P. Heparin reverses the procoagulant properties of stimulated endothelial cells. <span><span class="ref-journal">Thromb Haemost. </span>1996;<span class="ref-vol">75</span>:190\xe2\x80\x93195.</span> [<a href="/pubmed/8713800" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Thromb+Haemost&amp;title=Heparin+reverses+the+procoagulant+properties+of+stimulated+endothelial+cells&amp;author=Y+Cadroy&amp;author=D+Gaspin&amp;author=D+Dupouy&amp;author=JC+Lormeau&amp;author=B+Boneu&amp;volume=75&amp;publication_year=1996&amp;pages=190-195&amp;pmid=8713800&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B16"><span class="citation">Gori AM, Pepe G, Attanasio M, Falciani M, Abbate R, Prisco D, Fedi S, Giusti B, Brunelli T, Comeglio P, Gensini GF, Neri Serneri GG. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. <span><span class="ref-journal">Thromb Haemost. </span>1999;<span class="ref-vol">81</span>:589\xe2\x80\x93593.</span> [<a href="/pubmed/10235445" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Thromb+Haemost&amp;title=Tissue+factor+reduction+and+tissue+factor+pathway+inhibitor+release+after+heparin+administration&amp;author=AM+Gori&amp;author=G+Pepe&amp;author=M+Attanasio&amp;author=M+Falciani&amp;author=R+Abbate&amp;volume=81&amp;publication_year=1999&amp;pages=589-593&amp;pmid=10235445&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B17"><span class="citation">Pepe G, Giusti B, Attanasio M, Gori AM, Comeglio P, Martini F, Gensini G, Abbate R, Neri Serneri GG. Tissue factor and plasminogen activator inhibitor type 2 expression in human stimulated monocytes is inhibited by heparin. <span><span class="ref-journal">Semin Thromb Hemost. </span>1997;<span class="ref-vol">23</span>:135\xe2\x80\x93141.</span> [<a href="/pubmed/9200337" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Semin+Thromb+Hemost&amp;title=Tissue+factor+and+plasminogen+activator+inhibitor+type+2+expression+in+human+stimulated+monocytes+is+inhibited+by+heparin&amp;author=G+Pepe&amp;author=B+Giusti&amp;author=M+Attanasio&amp;author=AM+Gori&amp;author=P+Comeglio&amp;volume=23&amp;publication_year=1997&amp;pages=135-141&amp;pmid=9200337&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B18"><span class="citation">Marsh NA, Minter AJ, Chesterman CN. The effect of heparin and other glycosaminoglycans on levels of tissue plasminogen activator and plasminogen activator inhibitor in cultured human umbilical vein endothelial cells. <span><span class="ref-journal">Blood Coagul Fibrinolysis. </span>1990;<span class="ref-vol">1</span>:133\xe2\x80\x93138.</span> [<a href="/pubmed/1966669" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood+Coagul+Fibrinolysis&amp;title=The+effect+of+heparin+and+other+glycosaminoglycans+on+levels+of+tissue+plasminogen+activator+and+plasminogen+activator+inhibitor+in+cultured+human+umbilical+vein+endothelial+cells&amp;author=NA+Marsh&amp;author=AJ+Minter&amp;author=CN+Chesterman&amp;volume=1&amp;publication_year=1990&amp;pages=133-138&amp;pmid=1966669&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B19"><span class="citation">Murakami K, McGuire R, Cox RA, Jodoin JM, Bjertnaes LJ, Katahira J, Traber LD, Schmalstieg FC, Hawkins HK, Herndon DN, Traber DL. Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. <span><span class="ref-journal">Shock. </span>2002;<span class="ref-vol">18</span>:236\xe2\x80\x93241. doi: 10.1097/00024382-200209000-00006.</span> [<a href="/pubmed/12353924" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1097%2F00024382-200209000-00006" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Shock&amp;title=Heparin+nebulization+attenuates+acute+lung+injury+in+sepsis+following+smoke+inhalation+in+sheep&amp;author=K+Murakami&amp;author=R+McGuire&amp;author=RA+Cox&amp;author=JM+Jodoin&amp;author=LJ+Bjertnaes&amp;volume=18&amp;publication_year=2002&amp;pages=236-241&amp;pmid=12353924&amp;doi=10.1097/00024382-200209000-00006&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B20"><span class="citation">Gunther A, Lubke N, Ermert M, Schermuly RT, Weissmann N, Breithecker A, Markart P, Ruppert C, Quanz K, Ermert L, Grimminger F, Seeger W. Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2003;<span class="ref-vol">168</span>:1358\xe2\x80\x931365. doi: 10.1164/rccm.2201082.</span> [<a href="/pubmed/14644925" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1164%2Frccm.2201082" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Respir+Crit+Care+Med&amp;title=Prevention+of+bleomycin-induced+lung+fibrosis+by+aerosolization+of+heparin+or+urokinase+in+rabbits&amp;author=A+Gunther&amp;author=N+Lubke&amp;author=M+Ermert&amp;author=RT+Schermuly&amp;author=N+Weissmann&amp;volume=168&amp;publication_year=2003&amp;pages=1358-1365&amp;pmid=14644925&amp;doi=10.1164/rccm.2201082&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B21"><span class="citation">Dixon B, Campbell DJ, Santamaria JD. Elevated pulmonary dead space and coagulation abnormalities suggest lung microvascular thrombosis in patients undergoing cardiac surgery. <span><span class="ref-journal">Intensive Care Med. </span>2008</span>  [<a href="/pubmed/18301879" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Intensive+Care+Med&amp;title=Elevated+pulmonary+dead+space+and+coagulation+abnormalities+suggest+lung+microvascular+thrombosis+in+patients+undergoing+cardiac+surgery&amp;author=B+Dixon&amp;author=DJ+Campbell&amp;author=JD+Santamaria&amp;publication_year=2008&amp;pmid=18301879&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B22"><span class="citation">Nuckton TJ, Alonso JA, Kallet RH, Daniel BM, Pittet JF, Eisner MD, Matthay MA. Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome. <span><span class="ref-journal">N Engl J Med. </span>2002;<span class="ref-vol">346</span>:1281\xe2\x80\x931286. doi: 10.1056/NEJMoa012835.</span> [<a href="/pubmed/11973365" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1056%2FNEJMoa012835" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Pulmonary+dead-space+fraction+as+a+risk+factor+for+death+in+the+acute+respiratory+distress+syndrome&amp;author=TJ+Nuckton&amp;author=JA+Alonso&amp;author=RH+Kallet&amp;author=BM+Daniel&amp;author=JF+Pittet&amp;volume=346&amp;publication_year=2002&amp;pages=1281-1286&amp;pmid=11973365&amp;doi=10.1056/NEJMoa012835&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B23"><span class="citation">Bendstrup KE, Gram J, Jensen JI. Effect of inhaled heparin on lung function and coagulation in healthy volunteers. <span><span class="ref-journal">Eur Respir J. </span>2002;<span class="ref-vol">19</span>:606\xe2\x80\x93610. doi: 10.1183/09031936.02.00105202.</span> [<a href="/pubmed/11998987" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1183%2F09031936.02.00105202" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+Respir+J&amp;title=Effect+of+inhaled+heparin+on+lung+function+and+coagulation+in+healthy+volunteers&amp;author=KE+Bendstrup&amp;author=J+Gram&amp;author=JI+Jensen&amp;volume=19&amp;publication_year=2002&amp;pages=606-610&amp;pmid=11998987&amp;doi=10.1183/09031936.02.00105202&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B24"><span class="citation">Harenberg J, Malsch R, Angelescu M, Lange C, Michaelis HC, Wolf H, Heene DL. Anticoagulant effects and tissue factor pathway inhibitor after intrapulmonary low-molecular-weight heparin. <span><span class="ref-journal">Blood Coagul Fibrinol. </span>1996;<span class="ref-vol">7</span>:477\xe2\x80\x93483. doi: 10.1097/00001721-199606000-00008.</span> [<a href="/pubmed/8840001" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1097%2F00001721-199606000-00008" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood+Coagul+Fibrinol&amp;title=Anticoagulant+effects+and+tissue+factor+pathway+inhibitor+after+intrapulmonary+low-molecular-weight+heparin&amp;author=J+Harenberg&amp;author=R+Malsch&amp;author=M+Angelescu&amp;author=C+Lange&amp;author=HC+Michaelis&amp;volume=7&amp;publication_year=1996&amp;pages=477-483&amp;doi=10.1097/00001721-199606000-00008&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B25"><span class="citation">Mahadoo J, Hiebert LM, Jaques LB, Wright CJ. Endothelial sequestration of heparin administered by the intrapulmonary route. <span><span class="ref-journal">Artery. </span>1980;<span class="ref-vol">7</span>:438\xe2\x80\x93447.</span> [<a href="/pubmed/7213028" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Artery&amp;title=Endothelial+sequestration+of+heparin+administered+by+the+intrapulmonary+route&amp;author=J+Mahadoo&amp;author=LM+Hiebert&amp;author=LB+Jaques&amp;author=CJ+Wright&amp;volume=7&amp;publication_year=1980&amp;pages=438-447&amp;pmid=7213028&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B26"><span class="citation">El Solh AA, Choi G, Schultz MJ, Pineda LA, Mankowski C. Clinical and hemostatic responses to treatment in ventilator-associated pneumonia: role of bacterial pathogens. <span><span class="ref-journal">Crit Care Med. </span>2007;<span class="ref-vol">35</span>:490\xe2\x80\x93496. doi: 10.1097/01.CCM.0000253308.93761.09.</span> [<a href="/pubmed/17205031" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1097%2F01.CCM.0000253308.93761.09" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Crit+Care+Med&amp;title=Clinical+and+hemostatic+responses+to+treatment+in+ventilator-associated+pneumonia:+role+of+bacterial+pathogens&amp;author=AA+El+Solh&amp;author=G+Choi&amp;author=MJ+Schultz&amp;author=LA+Pineda&amp;author=C+Mankowski&amp;volume=35&amp;publication_year=2007&amp;pages=490-496&amp;pmid=17205031&amp;doi=10.1097/01.CCM.0000253308.93761.09&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B27"><span class="citation">Schultz MJ, Millo J, Levi M, Hack CE, Weverling GJ, Garrard CS, Poll T van der. Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. <span><span class="ref-journal">Thorax. </span>2004;<span class="ref-vol">59</span>:130\xe2\x80\x93135. doi: 10.1136/thorax.2003.013888.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1746934/">PMC free article</a>]</span> [<a href="/pubmed/14760153" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1136%2Fthorax.2003.013888" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Thorax&amp;title=Local+activation+of+coagulation+and+inhibition+of+fibrinolysis+in+the+lung+during+ventilator+associated+pneumonia&amp;author=MJ+Schultz&amp;author=J+Millo&amp;author=M+Levi&amp;author=CE+Hack&amp;author=GJ+Weverling&amp;volume=59&amp;publication_year=2004&amp;pages=130-135&amp;pmid=14760153&amp;doi=10.1136/thorax.2003.013888&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B28"><span class="citation">Bendstrup KE, Chambers CB, Jensen JI, Newhouse MT. Lung deposition and clearance of inhaled (99m)Tc-heparin in healthy volunteers. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>1999;<span class="ref-vol">160</span>:1653\xe2\x80\x931658.</span> [<a href="/pubmed/10556136" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Respir+Crit+Care+Med&amp;title=Lung+deposition+and+clearance+of+inhaled+(99m)Tc-heparin+in+healthy+volunteers&amp;author=KE+Bendstrup&amp;author=CB+Chambers&amp;author=JI+Jensen&amp;author=MT+Newhouse&amp;volume=160&amp;publication_year=1999&amp;pages=1653-1658&amp;pmid=10556136&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B29"><span class="citation">Bryan R, Feldman M, Jawetz SC, Rajan S, DiMango E, Tang HB, Scheffler L, Speert DP, Prince A. The effects of aerosolized dextran in a mouse model of <em>Pseudomonas aeruginosa </em>pulmonary infection. <span><span class="ref-journal">J Infect Dis. </span>1999;<span class="ref-vol">179</span>:1449\xe2\x80\x931458. doi: 10.1086/314755.</span> [<a href="/pubmed/10228067" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1086%2F314755" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Infect+Dis&amp;title=The+effects+of+aerosolized+dextran+in+a+mouse+model+of+Pseudomonas+aeruginosa+pulmonary+infection&amp;author=R+Bryan&amp;author=M+Feldman&amp;author=SC+Jawetz&amp;author=S+Rajan&amp;author=E+DiMango&amp;volume=179&amp;publication_year=1999&amp;pages=1449-1458&amp;pmid=10228067&amp;doi=10.1086/314755&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2481447&amp;issue-id=169506&amp;journal-id=9&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li></ul></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr />Articles from <span class="acknowledgment-journal-title">Critical Care</span> are provided here courtesy of <strong>BioMed Central</strong></div></div>\n            \n            \n        \n            \n        </div>\n        <!-- Book content -->\n    </div>\n    \n    <div id="rightcolumn" class="four_col col last">\n        <!-- Custom content above discovery portlets -->\n        <div class="col6">\n            \n        </div>\n        \n        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC2481447/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC2481447/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC2481447/pdf/cc6894.pdf">PDF (579K)</a></li> | <li><a href="#" data-citationid="PMC2481447" class="citationexporter ctxp">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2481447%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook" />\n                             Facebook\n                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2481447%2F&amp;text=A%20phase%201%20trial%20of%20nebulised%20heparin%20in%20acute%20lung%20injury"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter" />\n                             Twitter\n                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2481447%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus" />\n                             Google+\n                        </a></li></ul></div>\n        \n        <div id="ajax-portlets" data-pmid="18460218" data-aiid="2481447" data-aid="2481447" data-iid="169506" data-domainid="9" data-domain="ccforum" data-accid="PMC2481447" data-md5="2f1a39643dff578bbde1256a0c7b48fe"></div>\n                \n        <!-- Custom content below discovery portlets -->\n        <div class="col7">\n            \n        </div>\n    </div>\n</div>\n\n<!-- Custom content after all -->\n<div class="col8">\n    \n</div>\n<div class="col9">\n    \n</div>\n\n<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>\n<script>\n    (function($){\n        $(\'.skiplink\').each(function(i, item){\n            var href = $($(item).attr(\'href\'));\n            href.attr(\'tabindex\', \'-1\').addClass(\'skiptarget\'); // ensure the target can receive focus\n            $(item).on(\'click\', function(event){\n                event.preventDefault();\n                $.scrollTo(href, 0, {\n                    onAfter: function(){\n                        href.focus();\n                    }\n                });\n            });\n        });\n    })(jQuery);\n</script>\n\n\n\n<div id="body-link-poppers"></div>\n                        </div>\n                        <div class="bottom">\n                            \n                            <div id="NCBIFooter_dynamic">\n    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>\n    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2020-04-17T09:46:31-04:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=ptpmc102&amp;ncbi_phid=8A1B1B43E99AB9710000000005250522&amp;ncbi_session=8A1B1B43E99B3361_1317SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2481447%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>\n    \n</div>\n\n                            <div class="footer" id="footer">\n    \n    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>\n    <div id="external-disclaimer" class="offscreen_noflow">\n        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.\n    </div>    \n    <div id="ncbifooter" class="contact_info">      \n        <div id="footer-contents-right">\n            <div id="nlm_thumb_logo">\n                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>\n            </div>\n            <div id="nih_thumb_logo">\n                <a href="https://www.nih.gov" title="NIH">NIH</a>\n            </div>\n            <div id="hhs_thumb_logo">\n                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>\n            </div>\n            <div id="usagov_thumb_logo">\n                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>\n            </div>         \n        </div>\n        \n        <div id="footer-contents-left">\n            <p class="address vcard">\n                <span class="url">\n                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for\n                        Biotechnology Information</a>,\n                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>\n                <span class="adr">\n                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>\n                    <span class="region">MD</span>, <span class="postal-code">20894</span>\n                    <span class="country-name">USA</span>\n                </span>\n            </p>\n            \n            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>\n        </div>\n    </div>\n    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    \n    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>\n</div>\n                        </div>\n                    </div>\n                    <!--/.page-->\n                </div>\n                <!--/.wrap-->\n            </div><!-- /.twelve_col -->\n        </div>\n        <!-- /.grid -->\n\n        <span class="PAFAppResources"></span>\n        \n        <!-- BESelector tab -->\n        \n        \n        \n        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=ccforum&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC2481447/&amp;ncbi_app=pmc" /></noscript>\n        \n        \n        <!-- usually for JS scripts at page bottom -->\n        <!--<component id="PageFixtures" label="styles"></component>-->\n    \n\n<!-- 8A1B1B43E99B3361_1317SID /projects/PMC/PMCViewer@4.46 ptpmc102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->\n\n<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script></body>\n</html>'